Emerging role of Enterococcus spp in catheter-related infections: Biofilm formation and novel mechanisms of antibiotic resistance

Journal of Vascular Access

Volumn 5, Issue 1, 2004, Pages 3-9

  Donelli, Gianfranco ^a   Guaglianone, E ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Antibiotic resistance; Biliary stents; Biofilm; Enterococci; Intravascular catheters

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; ANTIBIOTIC AGENT; BACITRACIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CHLORAMPHENICOL; CLINDAMYCIN; ERYTHROMYCIN; PENICILLIN G; PENICILLINASE; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROBENIDINE; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; BIOFILM; BLOOD FLOW; CATHETER INFECTION; CRITICAL ILLNESS; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GENE TRANSFER; GRAM NEGATIVE INFECTION; HEALTH CARE COST; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INTRAVASCULAR CATHETER; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW; STENT; VASCULAR ACCESS;

EID: 2542506340     PISSN: 11297298     EISSN: None     Source Type: Journal    
DOI: 10.1177/112972980400500101     Document Type: Review

References (93)

1. Gin AS, Zhanel GG. Vancomycin-resistant enterococci (VRE). Ann Pharmacother 1996; 30: 615-24.
2. Murray BE. Vancomycin resistant enterococcal infections. N Engl J Med 2000; 342: 710-21.
3. Jett BD, Huycke MM, Gilmore MS. Virulence of enterococci. Clin Microbiol Rev 1994; 7: 462-78.
4. Spera RV, Farber BF, Multiply-resistant Enterococcus faecium. The nosocomial pathogen of the 1990s. JAMA 1992; 268: 2563-64.
5. Moellering RC Jr. Vancomycin-resistant enterococci. Clin Infect Dis 1998; 26: 1196-99.
6. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000; 13: 686-707.
7. Hancock LE, Gilmore MS. Pathogenicity of enterococci. In: Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Rood JI eds. Gram-positive pathogens. Washington, DC: ASM Press, 2000; 251-8.
8. Maki DG. Risk factors for nosocomial infection in intensive care. "Devices vs nature" and goals for the next decade. Arch Intern Med 1989; 149: 30-5.
9. Raad II, Bodey GP. Infectious complications of indwelling vascular catheters. Clin Infect Dis 1992; 15: 197-208.
10. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1994, 271: 1598-601.
11. Richet H, Hubert B, Nitemberg G, et al. Prospective multicenter study of vascular-catheter-related complications and risk factors for positive central-catheter cultures in intensive care unit patients. Clin Microbiol 1990; 28: 2520-5.
12. Collignon PJ. Intravascular catheter associated sepsis: a common problem. The Australian Study on Intravascular Catheter Associated Sepsis. Med J Aust 1994; 161: 374-8.
13. Donowitz LG, Wenzel RP, Hoyt JW. High risk of hospital-acquired infection in the ICU patient. Crit Care Med 1982; 10: 355-7.
14. Brown RB, Hosmer D, Chen HC, et al. A comparison of infections in different ICUs within the same hospital. Crit Care Med 1985; 13: 472-6.
15. Chandrasekar PH, Kruse JA, Matthews MF. Nosocomial infection among patients in different types of intensive care units at a city hospital. Crit Care Med 1986; 14: 508-10.
16. Brawley RL, Weber DJ, Samsa GP, et al. Multiple nosocomial infections: an incidence study. Am J Epidemiol 1989; 130: 769-80.
17. Baldassarri L, Gelosia A, Fiscarelli E, Donelli G. Microbial colonization of implanted silicone and polyurethane catheters. J Mater Sci Mater Med 1994; 5: 601-5.
18. Donelli G, De Paoli P, Fadda G, Marone P, Nicoletti G, Varaldo PE, CVC Study Group. A multicenter study on central venous catheter-associated infections in Italy. J Chemother 2001; 13 Spec No 1: 251-62.
19. Polderman KH, Girbes AR. Central venous catheter use. Part 2: infectious complications. Intensive Care Med 2002; 28: 18-28.
20. Safdar N, Maki DG. The pathogenesis of catheter-related bloodstream infection with noncuffed short-term central venous catheters. Intensive Care Med 2004; 30: 62-7.
21. Huycke MM, Sahm DF, Gilmore MS. Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future. Emerg Infect Dis 1998; 4: 239-49.
22. Fluit AC, Schmitz FJ, Verhoef J. Frequency of isolation of pathogens from bloodstream, nosocomial pneumonia, skin and soft tissue, and urinary tract infections occurring in European patients. Eur J Clin Microbiol Infect Dis 2001; 20: 188-91.
23. Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. Clin Chest Med 1999; 20: 303-16.
24. Shlaes DM, Levy J, Wolinsky E. Enterococcal bacteremia without endocarditis. Arch Intern Med 1981; 141: 578-81.
25. Patterson JE, Sweeney AH, Simms M, et al. An analysis of 110 serious enterococcal infections: Epidemiology, antibiotic susceptibility and outcome. Medicine (Baltimore) 1995; 74: 191-200.
26. Cotton PB. Critical appraisal of therapeutic endoscopy in biliary tract diseases. Annu Rev Med 1990; 41: 211-22.
27. Basoli A, Fiocca F, Di Rosa R, Baldassarri L, Donelli G. Biliary stent occlusion: a microbiological and scanning electron microscopy (SEM) investigation. In: Zanella ed. Advances in Abdominal Surgery. Kluwer Academic Publishers 1999; 69-80.
28. Di Rosa R, Basoli A, Donelli G, et al. A microbiological and morphological study of blocked biliary stents. Microb Ecol Health Dis 1999; 11: 84-8.
29. Magi G, Capretti R, Paoletti C, et al. Presence of a vanA-carrying Pheromone Response Plasmid (pBRG1) in a clinical isolate of Enteroroccus faecium. Antimicrob Agents Chemother 2003; 47: 1571-6.
30. Donelli G. Paoletti C, Baldassarri L, et al. Sex pheromone-response, clumping and slime production in enterococcal strains isolated from occluded biliary stents. J Clin Microbiol 2004 (in press).
31. Hakenbeck R, Coyette J. Resistant penicillin-binding proteins. Cell Mol Life Sci 1998; 54: 332-40.
32. Murray BE. The life and times of the Enterococcus. Clin Microbial Rev 1990; 3: 46-65.
33. Rybkine T, Mainardi JL, Sougakoff W, Collatz E, Gutmann L. Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of β-lactam resistance. J Infect Dis 1998; 178: 159-63.
34. Amyes SGB. Resistance to β-lactams- The permutations. J Chemother 2003; 15: 525-35.
35. Leclercq R, Derlot E, Duval J, et al. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus feacium. N Engl J Med 1988; 319: 157-61.
36. Uttley AH, Collins CH, Naidoo J, et al. Vancomycin-resistant enterococci. Lancet 1988; 1: 57-8.
37. Sahm DF, Kissinger J, Gilmore MS, et al. In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 1989; 33: 1588-91.
38. Boyce JM. Vancomycin-resistant enterococcus. Infect Dis Clin North Am 1997; 11: 367-84.
39. Zanella RC, Valdetaro F, Lovgren M, et al. First confirmed case of a vancomycin-resistant Enterococcus faecium with vanA phenotype from Brazil: isolation from a meningitis case in Sao Paulo. Microb Drug Resist 1999; 5: 159-62.
40. McCarthy KM, Van Nierop W, Duse A, et al. Control of an outbreak of vancomycin-resistant Enterococcus faecium in an oncology ward in South Africa: effective use of limited resources. J Hosp Infect 2000; 44: 294-300.
41. Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin-resistance. Infect Control Hosp Epidemiol 1995; 16: 105-13.
42. Arthur M, Reynolds PE, Courvalin P. Glycopeptide resistance in enterococci. Trends Microbiol 1996; 4: 401-7.
43. Fines M, Perichon B, Reynolds PE, Sahm DF, Courvalin P. VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis. Antimicrob Agents Chemother 1999; 43: 2161-4.
44. Arias CA, Courvalin P, Reynolds PE. vanC gene cluster of vancomycin-resistant Enterococcus gallinarum BM4174. Antimicrob Agents Chemother 2000; 44: 1660-6.
45. McKessar SJ, Berry AM, Bell JM, Turnidge JD, Paton JC. Genetic characterization of vanG a novel vancomycin resistance locus of Enterococcus faecalis. Antimicrob Agents Chemother 2000; 44: 3224-8.
46. Power EG, Abdulla YH, Talsania HG, Spice W, Aathithan S, French GL. vanA genes in vancomycin-resistant clinical isolates of Oerskovia turbata and Arcanobacterium (Corynebacterium) haemolyticum. J Antimicrob Chemother 1995; 36: 595-606.
47. Ligozzi M, Cascio GL, Fontana R. A vanA gene cluster in a vancomycin-resistant clinical isolate of Bacillus circulans. Antimicrob Agents Chemother 1998; 42: 2055-59.
48. Mevius D, Devriese L, Butaye P, Vandame P, Verschure M, Veldman K. Isolation of glycopeptide resistant Streptococcus gallolyticus strains with vanA, vanB and both vanA and vanB genotypes from faecal samples of veal calves in the Netherlands. J Antimicrob Chemother 1998; 42: 275-6.
49. Malathum K, Murray BE. Vancomycin-resistant enterococci: recent advances in genetics epidemiology and therapeutic options. Drug Resist Updat 1999; 2: 224-43.
50. Arthur M, Reynolds PE, Depardieu F, et al. Mechanisms of glycopeptide resistance in enterococci. J Infect 1996; 32: 11-6.
51. Arthur M, Depardieu F, Molinas C, Reynolds P, Courvalin P. The vanZ gene of Tn1546 from Enterococcus faecium BM4147 confers resistance to teicoplanin. Gene 1995; 154: 87-92.
52. Arthur M, Molinas C, Depardieu F, Courvalin P. Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J Bacteriol 1993; 175: 117-27.
53. Leclercq R, Courvalin P. Resistance to glycopeptides in enterococci. Clin Infect Dis 1997; 24: 545-54.
54. Patel R. Enterococcal-type glycopeptide resistance genes in non-enterococcal organisms. FEMS Microbiol Lett 2000; 185: 1-7.
55. Marshall CG, Lessard IA, Park I, Wright GD. Glycopeptide antibiotic resistance genes in glycopeptide-producing organisms. Antimicrob Agents Chemother 1998; 42: 2215-20.
56. Rippere K, Patel R, Uhl JR, et al. DNA sequence resembling vanA and vanB in the vancomycin-resistant biopesticide Bacillus popilliae. J Infect Dis 1998; 178: 584-88.
57. Arthur M, Molinas C, Bugg TD, Wright GD, Walsh CT, Courvalin P. Evidence for in vivo incorporation of D-lactate into peptidoglycan precursors of vancomycin-resistant enterococci. Antimicrob Agents Chemother 1992; 36: 867-69.
58. Safdar N, Kluger DM, Maki DG. A review of risk factors for catheter-related bloodstream infection caused by percutaneously inserted, noncuffed central venous catheters: implications for preventive strategies. Medicine (Baltimore) 2002; 81: 46649.
59. Costerton JW. Overview of microbial biofilms. J Indus Microbiol 1995; 15: 137-40.
60. O'Toole CA, Kaplan H, Kolter R. Biofilm formation as microbial development. Annu Rev Microbiol 2000; 54: 49-79.
61. Reifsteck F, Wee S, Wilkinson BJ. Hydrophobicity-hydrophilicity of staphylococci. J Med Microbiol 1987; 24: 65-73.
62. Baldassarri L, Christensen GD, Donelli G. Is slime the virulence factor in staphylococcal biomaterial-associated infections? Microecol Ther 1995; 25: 103-7.
63. Baldassarri L, Donelli G, Gelosia A, Voglino MC, Simpson A, Christensen GD. Purification and characterization of the staphylococcal slime-associated antigen and its occurrence among Staphylococcus epidermidis clinical isolates. Infect Immun 1996; 64: 3410-5.
64. Baldassarri L, Donelli G, Gelosia A, Simpson AW, Christensen GD. Expression of slime interferes with in vitro detection of host protein receptors of Stalphylococcus epidermidis. Infect Immun 1997; 65: 1522-6.
65. Ammendolia MG, Di Rosa R, Montanaro L, Arciola CR, Baldassarri L. Slime production and expression of the slime-associated antigen by staphylococcal clinical isolates. J Clin Microbiol 1999; 37: 3235-8.
66. Arciola CR, Baldassarri L, Montanaro L. Presence of icaA and icaD genes and slime production in a collection of staphylococcal strains from catheter-associated infections. J Clin Microbiol 2001; 39: 2151-6.
67. Arciola CR, Campoccia D, Gamberini S, Cervellati M, Donati E, Montanaro L. Detection of slime production by means of an optimised Congo red agar plate test based on a colourimetric scale in Staphylococcus epidermidis clinical isolates genotyped for ica locus. Biomaterials 2002; 23: 4233-9.
68. Danese PN, Pratt LA, Kolter R. Exopolysaccharide production is required for development of Escherichia coli K-12 biofilm architecture. J Bacteriol 2000; 182: 3593-6.
69. Donelli G, Leone F, Mazzella P, Ginnetti F, Rossi A, Fadda G. Qualità dei cateteri vascolari e rischio infettivo, associato. G Ital Chemioter 2000; 47: 29-35.
70. Farber BF, Kaplan MH, Clogston AG. Staphyloroccus epidermidis extracted slime inhibits the antimicrobial action of glycopeptide antibiotics. J Infect Dis 1990; 161: 37-40.
71. Guzman CA, Pruzzo C, Lipira G, Callegari L. Role of adherence in pathogenesis of Enterococcus faecalis urinary tract infection and endocarditis. Infect Immun 1989; 57: 1834-8.
72. Kreft B, Marre R, Schramm U, Wirth R. Aggregation substance of Enterococcus faecalis mediates adhesion to cultured renal tubular cells. Infect Immun 1992; 60: 25-30.
73. Shiono A, Ike Y. Isolation of Enterococcus fiaecalis clinical isolates that efficiently adhere to human bladder carcinoma T24 cells and inhibition of adhesion by fibronectin and trypsin treatment. Infect Immun 1999; 67: 1585-92.
74. Donlan RM. Biofilm formation: a clinically relevant microbiological process. Clin Infect Dis 2001; 33: 1387-92.
75. Guzman CA, Pruzzo C, Platè M, Guardati MC, Calegari L. Serum dependent expression of Enterococcus faecalis adhesins involved in the colonization of heart cells. Microb Pathog 1991; 11: 399-409.
76. Lowe AM, Lambert PA, Smith AW. Cloning of an Enterococcus faecalis endocarditis antigen: homology with adhesins from some oral streptococci. Infect Immun 1995; 63: 703-6.
77. Rich RL, Kreikemeyer B, Owens RT, et al. Ace is a collagen-binding MSCRAMM from Enterococcus faecalis. J Biol Chem 1999; 274: 26939-45.
78. Clewell DB. Bacterial sex-pheromone-induced plasmid transfer. Cell 1993; 73: 9-12.
79. Joyanes P, Pascual A, Martinez-Martinez L, Hevia A, Perea EJ. In vitro adherence of Enterococcus faecalis and Enterococcus faecium to urinary catheters. Eur J Clin Microbiol Infect Dis 2000; 19: 124-27.
80. Olmsted SB, Dunny GM, Erlandsen SL, Wells CL. Plasmid-encoded surface protein on Enterococcus faecalis augments its internalization by cultured intestinal epithelial cells. J Infect Dis 1994; 170: 1549-56.
81. Toledo-Arana A, Valle J, Solano C, et al. The enterococcal surface protein, Esp, is involved in Enterococcus faecalis biofilm formation. Appl Environ Microbiol 2001; 67: 4538-45.
82. Cucarella C, Solano C, Valle J, Amorena B, Lasa I, Penades JR. Bap, a Staphylococcus aureus surface protein involved in biofilm formation. J Bacteriol 2001; 183: 2888-96.
83. Creti R, Imperi M, Bertuccini L, et al. Survey for virulence determinants among Enterococcus faecalis isolated from different sources. J Med Microbiol 2004; 53: 13-20.
84. Chow JW, Thal LA, Perri MB, et al. Plasmid-associated hemolysin and aggregation substance production contribute to virulence in experimental enterococcal endocarditis. Antimicrob Agents Chemother 1993; 37: 2474-77.
85. Gilmore MS ed. The Enterococci: Pathogenesis, Molecular Biology, and Antibiotic Resistance. Washington DC: American Society of Microbiology 2002.
86. Makinen PL, Clewell DB, An F, Makinen KK. Purification and substrate specificity of a strongly hydrophobic extracellular metalloendopeptidase ("gelatinase") from Streptococcus faecalis (strain OG1-10). J Biol Chem 1989; 264: 3325-34.
87. Archimbaud C, Shankar N, Forestier C, et al. In vitro adhesive properties and virulence factors of Enterococcus faecalis strains. Res Microbiol 2002; 153: 75-80.
88. Foley I, Gilbert P. In-vitro studies of the activity of glycopeptide combinations against Enterococcus faecalis biofilms. J Antimicrob Chemother 1997; 40: 667-72.
89. Leung JW, Lau GT, Sung JJ, Costerton JW. Decreased bacterial adherence to silver-coated stent material: an in vitro study. Gastrointest Endosc 1992; 38: 338-40.
90. Donelli G, Francolini I. Efficacy of antiadhesive, antibiotic and antiseptic coatings in preventing catheter-related infections. J Chemother 2001; 13: 595-606.
91. Donelli G, Francolini I, Piozzi A, Di Rosa R, Marconi W. New polymer-antibiotic systems to inhibit bacterial biofilm formation: a suitable approach to prevent central venous catheter-associated infections. J Chemother 2002; 14: 501-7.
92. Donelli G, Francolini I, Di Carlo V, et al. Protocollo per la prevenzione, diagnosi e terapia delle infezioni associate a cateteri venosi centrali. Rapporti ISTISAN 02/34, 2002; iii, 33p.
93. De Gaudio AR, Di Filippo A. Device-related infections in critically ill patients. Part I: Prevention of catheter-related bloodstream infections. J Chemother 2003; 15: 419-27.